Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging
-
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
-
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
-
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
-
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
-
MAX Power Mining Corp. Announces Results of Annual General and Special Meeting
-
Momcozy launches Brand Day Campaign and New Initiatives, Empowering Moms Through Cozy Evolution
-
35/2024・Trifork Group AG – Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them
-
My Sea to Sky and Others Address Misinformation About LNG through a New Advertising Campaign - Our Future is Now
-
EagleView Captures High-Resolution Aerial Imagery and Data of Hurricane Francine at Unmatched 1-Inch GSD, Supporting Immediate Recovery Efforts
-
“The workers deserve to be compensated too”: UFCW Local 247 responds to $4-million dollar payout to B.C. tree-fruit growers
-
Taiwan Tourism’s Brand 3.0 Surges in New York “Taiwan - Waves of Wonder” the New Global Tidal Shift
-
Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024
-
Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024
-
KFSHRC Revolutionizes Patient Care with Pioneering Experience Ambassadors Program
-
MADD Canada Holds Second Annual Ceremony for Ontario Victims of Impaired Driving
-
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
-
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESM
-
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on
-
Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
-
Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
-
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
-
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
-
Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors
-
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
-
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
-
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non
-
Eco Oro Announces Change in Management Team and Board
-
Gran Tierra Energy Inc. Announces Pricing of an Additional $150 Million Aggregate Principal Amount of its 9.500% Senior Secured Amortizing Notes due 2029
-
KBW Announces Index Rebalancing for Third-Quarter 2024
-
Company Statement on FDA Advisory Committee Meeting
-
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.
-
Edward Jones expands presence in Atlantic Canada with first woman-led branch in Fredericton, New Brunswick
-
Prairie Provident Announces Loan Amendments and $13.2 Million Equity Rights Offering With $12 Million of Committed Participation
-
Carbeeza Inc. Announces Private Placement Extension
-
Greystone Logistics Reports Strong Year-End Earnings
-
Trade24Seven.com review - Empowering traders in India and Japan with a robust platform and financial education
-
VERSES AI Inc. Announces 2024 AGSM Results
-
Prospect Floating Rate and Alternative Income Fund Announces an Increased 8.14% Annualized Total Cash Distribution Percentage Rate on Net Asset Value for June 2024
-
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Oddity Tech (NASDAQ: ODD) Investors to Inquire About a Securities Fraud Class Action by September 17, 2024
-
LemVega Capital, the Leading Investment Management Firm, on Track to Become a Global Financial Powerhouse
-
VALUE LINE, INC. ANNOUNCES FIRST QUARTER EARNINGS
-
Northwest residents are concerned about wildfire but one in four people admit they don’t prepare
-
Upwork Confirms Receipt and Comments on Shareholder Letter
-
Ready Capital Corporation Declares Third Quarter 2024 Dividends
-
Nevada Zinc Appoints Dan Gosselin to the Board of Directors
-
Goldmoney Receives Exemption from Canadian Securities Regulators for its Precious Metals Purchase and Storage Services in Canada
-
Asante Files Financial and Operating Results for the Quarter Ended July 31, 2024
-
Westport Announces At-the-Market Equity Offering Program
-
Peyto Exploration & Development Corp. Confirms Monthly Dividend for October 15, 2024
